Enter Note Done
Go to previous page in this tab
Session
  • Presentation | Oral Presentations - Impact of COVID-19 on Diabetes—Epidemiologic Evidence
  • Oral Presentations
  • 269-OR - No BMI Increase during the COVID-19 Pandemic in Children and Adults with T1D in Three Continents: Joint Analysis of ADDN, T1DX, and DPV Registries [Board No. 269]
  • 217 (Level 2)
    8
    Set Timezone
K.Narayan: None. D.M.Maahs: Advisory Panel; ; Abbott Diabetes, Eli Lilly and Company, Medtronic, Novo Nordisk, Sanofi, Consultant; ; Aditx Therapeutics, Inc., Biospex. R.W.Holl: None. M.E.Craig: None. M.Auzanneau: None. N.Noor: None. S.Rompicherla: None. O.Ebekozien: None. S.Glastras: None. C.E.Smart: None. S.Bachmann: None. R.Welp: None.
Type
Theme Area
CME Hrs.
Livestream Session

269-OR - No BMI Increase during the COVID-19 Pandemic in Children and Adults with T1D in Three Continents: Joint Analysis of ADDN, T1DX, and DPV Registries
Main Session
Discussion